MELBOURNE, Vic, Australia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (OTCQB:INNMF ASX:ATX), based in Melbourne, Australia and focused on developing new therapies for hard to treat cancers, today announced that Dr Chris Burns, CEO and Managing Director, will present live at Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on December 11th.
DATE: December 11th
TIME: 3:00 PM ET
LINK: REGISTER HERE
Available for 1x1 meetings: December 11, 15 and 16, after 3pm ET. Schedule 1x1 Meetings here
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
Recent Company Highlights
- Top-line data from ACCENT pancreatic cancer trial indicates superior efficacy of narmafotinib dosed in combination with chemotherapy over chemotherapy alone
- AMPLICITY P1b pancreatic cancer trial, being conducted in the US and Australia, commenced dosing Sept 2025
- Fast Track Designation and Orphan Drug Designation in pancreatic cancer
- Promising preclinical data in combination with kRAS inhibitors illustrates potential expansion opportunities in pancreatic cancer
- Positive preclinical data in ovarian cancer as additional therapeutic opportunity
About Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
CONTACTS:
Amplia Therapeutics Limited
Dr Chris Burns, CEO and Managing Director
Email: chris@ampliatx.com; Tel: + 61 3 9123 1140
Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
